Last reviewed · How we verify
CLARA
Clara, marketed by Hospices Civils de Lyon, is a small molecule drug with a key composition patent expiring in 2028. Its mechanism of action involves interacting with a specific target in the body, providing a targeted therapeutic approach. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | CLARA |
|---|---|
| Sponsor | Hospices Civils de Lyon |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Predicate and Lay User-HCP Comparison Study of a Multi-Level Urine hCG Pregnancy Test
- Artificial Intelligence-Driven Medipixel Fractional Flow Reserve Versus Invasive Fractional Flow Reserve-Guided PCI Trial (AIM-FFR Trial) (NA)
- Silicon Valley Guaranteed Income Project (NA)
- Validation of Clara Cell Protein as a Novel Diagnostic Biomarker for the Differentiation of Cardiogenic Pulmonary Edema From Non-Cardiogenic Pulmonary Edema
- A Phase 1/2 Study of AURN001 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction (ABA-1) (PHASE1,PHASE2)
- The Bone Thickness of Infrazygomatic Crest Was Measured on CBCTs
- Motor-Cognitive Training for Motoric Cognitive Risk Syndrome (NA)
- Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CLARA CI brief — competitive landscape report
- CLARA updates RSS · CI watch RSS
- Hospices Civils de Lyon portfolio CI